## Catherine Guette

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8033309/publications.pdf

Version: 2024-02-01

47 2,079 papers citations

23 44
h-index g-index

51 51 docs citations

51 times ranked 3391 citing authors

#	Article	IF	CITATIONS
1	First report in a river in France of the benthic cyanobacterium Phormidium favosum producing anatoxin-a associated with dog neurotoxicosis. Toxicon, 2005, 45, 919-928.	0.8	276
2	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Research, 2015, 17, 43.	2.2	248
3	The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata. Phytochemistry, 2006, 67, 2071-2077.	1.4	139
4	Differential Protein Modulation in Midguts of Aedes aegypti Infected with Chikungunya and Dengue 2 Viruses. PLoS ONE, 2010, 5, e13149.	1.1	130
5	Quercitrin: An Antileishmanial Flavonoid Glycoside fromKalanchoe pinnata. Planta Medica, 2006, 72, 81-83.	0.7	118
6	A Quantitative Proteomic Approach of the Different Stages of Colorectal Cancer Establishes OLFM4 as a New Nonmetastatic Tumor Marker. Molecular and Cellular Proteomics, 2011, 10, M111.009712.	2.5	103
7	Glioblastomaâ€associated stromal cells ( <scp>GASCs</scp> ) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties. Journal of Pathology, 2014, 233, 74-88.	2.1	67
8	A Proteomic Approach for Plasma Biomarker Discovery with iTRAQ Labelling and OFFGEL Fractionation. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-8.	3.0	65
9	Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment. Cell Death and Disease, 2019, 10, 199.	2.7	62
10	Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples. Molecular and Cellular Proteomics, 2015, 14, 2936-2946.	2.5	61
11	Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity. Cell Cycle, 2019, 18, 2385-2397.	1.3	61
12	Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Science, 2008, 6, 27.	0.7	60
13	Isolation and characterization of Psalmopeotoxin I and II: two novel antimalarial peptides from the venom of the tarantulaPsalmopoeus cambridgei. FEBS Letters, 2004, 572, 109-117.	1.3	58
14	Comparison of Spheroids Formed by Rat Glioma Stem Cells and Neural Stem Cells Reveals Differences in Glucose Metabolism and Promising Therapeutic Applications. Journal of Biological Chemistry, 2012, 287, 33664-33674.	1.6	55
15	Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy. Cell Death and Disease, 2018, 9, 199.	2.7	47
16	Bromation régiosélective en série aromatique. l: Monobromation en position para de phénols et d'aminés aromatiques par le tribromure de tétrabutylammonium. Canadian Journal of Chemistry, 1989, 67, 2061-2066.	0.6	45
17	How should we define STAT3 as an oncogene and as a potential target for therapy?. Jak-stat, 2013, 2, e24716.	2.2	43
18	BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nature Communications, 2017, 8, 1123.	5.8	43

#	Article	IF	CITATIONS
19	Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. Oncotarget, 2015, 6, 409-426.	0.8	42
20	Modulation of Kv4.2 channels by a peptide isolated from the venom of the giant bird-eating tarantula Theraphosa leblondi. Toxicon, 2004, 43, 923-932.	0.8	34
21	Peptide profiling by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry of the Lasiodora parahybana tarantula venom gland. Toxicon, 2006, 47, 640-649.	0.8	31
22	Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis. Oncotarget, 2015, 6, 43342-43362.	0.8	27
23	Nanospray analysis of the venom of the tarantulaTheraphosa leblondi: a powerful method for direct venom mass fingerprinting and toxin sequencing. Rapid Communications in Mass Spectrometry, 2004, 18, 1024-1032.	0.7	24
24	Solution structure of PcFK1, a spider peptide active against Plasmodium falciparum. Protein Science, 2006, 15, 628-634.	3.1	24
25	Kalanchosine Dimalate, an Anti-inflammatory Salt fromKalanchoebrasiliensis. Journal of Natural Products, 2006, 69, 815-818.	1.5	23
26	Olfactomedinâ€4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers. Proteomics - Clinical Applications, 2015, 9, 58-63.	0.8	18
27	Biomarkers of tumor invasiveness in proteomics (Review). International Journal of Oncology, 2020, 57, 409-432.	1.4	18
28	OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATHâ€Based Proteomic Approach. Proteomics, 2019, 19, e1800446.	1.3	17
29	S100A4 Is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma. Cancers, 2020, 12, 939.	1.7	17
30	iTRAQâ€Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Tripleâ€Negative Breast Cancer Tumors. Proteomics, 2019, 19, 1800484.	1.3	14
31	tRNA biogenesis and specific aminoacyl-tRNA synthetases regulate senescence stability under the control of mTOR. PLoS Genetics, 2021, 17, e1009953.	1.5	11
32	Isolation and structure of cyclosenegalins A and B, novel cyclopeptides from the seeds of Annona senegalensis. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 2712-2718.	1.3	10
33	Cross-Species Proteomics Identifies CAPG and SBP1 as Crucial Invasiveness Biomarkers in Rat and Human Malignant Mesothelioma. Cancers, 2020, 12, 2430.	1.7	9
34	Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma. Oncotarget, 2018, 9, 16311-16329.	0.8	9
35	Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: A multicentric 2004 national PHRC study. International Journal of Oncology, 2012, 41, 92-104.	1.4	8
36	Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy‑induced senescence escape. International Journal of Oncology, 2021, 60, .	1.4	8

3

#	Article	IF	CITATIONS
37	Bromation régiosélective en série aromatique. II. Approche théorique du mécanisme de la substitution électrophile par l'ion tribromure Br3â^. Canadian Journal of Chemistry, 1990, 68, 464-470.	0.6	7
38	Affinity capture using chimeric membrane proteins bound to magnetic beads for rapid ligand screening by matrixâ€assisted laser desorption/ionization timeâ€ofâ€flight mass spectrometry. Rapid Communications in Mass Spectrometry, 2009, 23, 745-755.	0.7	6
39	Proteomics Approaches to Define Senescence Heterogeneity and Chemotherapy Response. Proteomics, 2019, 19, 1800447.	1.3	6
40	Lymphoid Organ Proteomes Identify Therapeutic Efficacy Biomarkers Following the Intracavitary Administration of Curcumin in a Highly Invasive Rat Model of Peritoneal Mesothelioma. International Journal of Molecular Sciences, 2021, 22, 8566.	1.8	5
41	An unusual cleavage reaction of a peptide observed during dithiotreitol and tris(2-carboxyethyl)phosphine reduction: application to sequencing of HpTx2 spider toxin using nanospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2004, 18, 1317-1323.	0.7	4
42	Intestinal cell targeting of a stable recombinant Cu–Zn SOD from Cucumis melo fused to a gliadin peptide. Journal of Biotechnology, 2012, 159, 99-107.	1.9	4
43	Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies. Frontiers in Pharmacology, 0, 13, .	1.6	3
44	Twoâ€step OFFGEL approach for effective peptide separation compatible with iTRAQ labeling. Proteomics, 2013, 13, 3261-3266.	1.3	2
45	OFFGEL-Isoelectric Focusing Fractionation for the Analysis of Complex Proteome. Neuromethods, 2011, , 145-158.	0.2	2
46	RE: Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). Journal of the National Cancer Institute, 2020, 112, 863-864.	3.0	1
47	Abstract P2-04-07: Gene-expression molecular subtyping of immunohistochemistry-typed triple-negative breast cancer tumours. , 2015, , .		0